Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, noviembre 05
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Merck & Co Inc
MRK
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$150.36
5.69
3.93%
Últ. Act.: Nov 4, 7:45 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 se publicaron el jue oct 29th, antes de la apertura del mercado
Conferencia telefónica:
La conferencia telefónica más reciente comenzó a las 9:00 a. m., hace 6 días
Haz clic para ver el webcast
Merck & Co Financials
Merck & Co (MRK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027
Merck beats Q3 estimates and raises 2026 guidance as Keytruda and Winrevair propel quarterly sales past Wall Street expectations.
Vandana Singh
Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
Piero Cingari
PRO
Merck & Co Raises FY2026 Adj EPS Guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 Est; Raises FY2026 Sales Guidance from $66.300B-$67.300B to $66.800B-$67.300B vs $67.052B Est
Merck & Co (NYSE:MRK) raises FY2026 Adj EPS guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 analyst estimate. Raises FY2026 sales outlook from $66.300 billion-$67.300 billion to $66.800 billion-$67.300 billion vs
Benzinga Newsdesk
PRO
Merck Q3 KEYTRUDA/KEYTRUDA QLEX Sales $8.60B (+6% Y/Y)
Total Worldwide Sales Were $18.1 Billion (5% Growth; 4% Growth ex-FX)KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.6 Billion (6% Growth; 6% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $830 MillionWINREVAIR Sales Were $694
Benzinga Newsdesk
PRO
Merck & Co Q3 Adj. EPS $2.49 Beats $2.08 Estimate, Sales $18.085B Beat $17.313B Estimate
Merck & Co (NYSE:MRK) reported quarterly earnings of $2.49 per share which beat the analyst consensus estimate of $2.08 by 19.71 percent. This is a 3.49 percent decrease over earnings of $2.58 per share from the
Benzinga Newsdesk
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds dip to 47% as Wall Street weighs a tech selloff, Amazon earnings, PCE inflation, and cooling oil.
Rishabh Mishra
